Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is currently the standard-of-care treatment for patients with nAMD, and anti-VEGF therapy has been shown to be highly effective in reducing blindness due to nAMD [2,3,4,5]. This evidence concerns the gene VEGFA and blindness (disorder).